文献速递其他结缔组织病

饮食干预对系统性硬化症胃肠道受累疗效的系统综述

The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2018-12-06

该系统综述评估饮食干预对系统性硬化症胃肠道症状的疗效,检索EMBASE和MEDLINE共1032篇文献,仅3项小型开放非随机研究符合标准。益生菌和低FODMAP饮食后患者报告的胃肠道症状改善,但个体化营养咨询无改善;证据基础有限,指南应审慎推荐。

要点

  • 仅3项小型开放非随机研究支持饮食干预,证据有限。
  • 益生菌和低FODMAP饮食后患者报告胃肠道症状改善。
  • 个体化营养咨询未显示胃肠道症状改善。

核心结论

  • 支持饮食干预治疗系统性硬化症胃肠道受累的证据基础目前有限,临床实践指南应审慎推荐。

研究设计与样本

  • 系统文献综述,方案按PRISMA指南制定并注册于PROSPERO(CRD42018103549),检索EMBASE和MEDLINE。

主要发现

  • 共识别1032篇文章,仅3篇符合全文数据提取条件。
  • 3项研究均为小型(平均每项19名受试者)、单中心、短期(平均6周)、开放标签非随机研究,分别评估益生菌、低FODMAP饮食和高度个体化医学营养治疗咨询。
  • 益生菌治疗和低FODMAP饮食后患者报告的胃肠道症状结局评估有改善,而定制饮食和营养咨询后无改善。
  • 非随机研究偏倚风险评估工具(RoBANS)在3项研究中均判定混杂变量和评估者盲法为高偏倚风险。

临床怎么用

  • 临床实践指南对饮食干预推荐应采取审慎态度,不应基于有限证据做强烈推荐。
  • 大型患者注册登记可帮助获取饮食干预疗效的实践证据,以指导未来指南。

局限性

  • 纳入研究数量少(3项)、样本量小(平均19例)、单中心、短期(平均6周)、开放标签非随机设计。
  • 研究间异质性大,无法进行定量合成,仅作定性综合。
  • 3项研究在混杂变量和评估者盲法方面均存在高偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrointestinal involvement in systemic sclerosis is common and a major cause of disease-related morbidity. Patients increasingly enquire about dietary modifications that may help with gastrointestinal symptoms. Many clinical practice reviews and treatment guidelines make specific reference to dietary modifications in the management of gastrointestinal involvement in systemic sclerosis. We report the findings of a systematic literature review designed to evaluate the evidence to support dietary modification in the management of gastrointestinal symptoms of systemic sclerosis. METHODS: A systematic literature review protocol was developed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered with the International prospective register of systematic reviews (CRD42018103549). Standardised searches of EMBASE and MEDLINE were undertaken to identify studies reporting the outcome of dietary modification in the management of gastrointestinal symptoms of systemic sclerosis. Wide heterogeneity in study design, interventions and study outcomes necessitated a qualitative data synthesis. RESULTS: Our standardised searches identified 1032 articles, of which 3 were deemed eligible for full data extraction. These studies were small (mean 19 subjects per study), single centre, short-term (mean 6 week duration) open-label non-randomised studies examining the role of probiotics, low-fermentable oligo-saccharides, disaccharides, monosaccharides, and polyol (low-FODMAP) diet and highly individualised medical nutrition therapy counselling, respectively. Improvements in patient-reported outcome assessment of gastrointestinal symptoms were reported after intervention with probiotic therapy and low-FODMAP diet but not following tailored dietary and nutritional counselling. The Risk of Bias Assessment Tool for Nonrandomized Studies identified high risk-of-bias for confounding variables and blinding of assessors in each of the three studies evaluated. CONCLUSIONS: The evidence-base to support dietary modification for gastrointestinal involvement in systemic sclerosis is currently limited and clinical practice guidelines should take a measured approach to such recommendations. The emergence of large patient registries could facilitate the capture of vital practice-based evidence regarding the efficacy of dietary modification in the management of gastrointestinal involvement in systemic sclerosis to inform future clinical practice guidelines.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Smith E, Pauling JD. The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum. 2018. PMID: 30612705. doi:10.1016/j.semarthrit.2018.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。